biotech · Alzheimer Disease · Friedreich Ataxia · LXEO
Lexeo Therapeutics
Lexeo Therapeutics is a biotech organization headquartered in New York, USA. It trades on NYSE under ticker LXEO. Primary therapeutic focus areas include Alzheimer Disease, Friedreich Ataxia, Arrhythmogenic Cardiomyopath
New York, USA HQ
2018 Founded
91 Employees
Public company Type
LXEO · NYSE Ticker
Company details
- Status
- Public
- HQ
- New York, USA
- Founded
- 2018
- Employees
- 91
- Programs
- 3
- Drugs
- 4
- Patents
- 0
LX2020
Phase 2 · gene therapy · Arrhythmogenic Cardiomyopathy
LX2020 for Arrhythmogenic Cardiomyopathy is a Phase 2 program (gene_therapy) at Lexeo Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code LX2020-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lexeo Therapeutics
- Phase
- Phase 2
- Modality
- gene_therapy
- Indication
- Arrhythmogenic Cardiomyopathy
- Status
- active
- Trials
- 1